NKTX vs. NKTR, KMDA, SBTX, ERAS, ADCT, ATAI, MRSN, VSTM, AVIR, and PGEN
Should you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Nektar Therapeutics (NKTR), Kamada (KMDA), Silverback Therapeutics (SBTX), Erasca (ERAS), ADC Therapeutics (ADCT), Atai Life Sciences (ATAI), Mersana Therapeutics (MRSN), Verastem (VSTM), Atea Pharmaceuticals (AVIR), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry.
Nkarta (NASDAQ:NKTX) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
In the previous week, Nkarta had 2 more articles in the media than Nektar Therapeutics. MarketBeat recorded 18 mentions for Nkarta and 16 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.48 beat Nkarta's score of 0.03 indicating that Nektar Therapeutics is being referred to more favorably in the news media.
Nektar Therapeutics received 579 more outperform votes than Nkarta when rated by MarketBeat users. However, 72.73% of users gave Nkarta an outperform vote while only 70.61% of users gave Nektar Therapeutics an outperform vote.
80.5% of Nkarta shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 5.6% of Nkarta shares are owned by company insiders. Comparatively, 3.1% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Nkarta has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -195.02%. Nkarta's return on equity of -34.13% beat Nektar Therapeutics' return on equity.
Nkarta presently has a consensus target price of $17.83, indicating a potential upside of 159.21%. Nektar Therapeutics has a consensus target price of $3.50, indicating a potential upside of 91.26%. Given Nkarta's stronger consensus rating and higher possible upside, equities analysts clearly believe Nkarta is more favorable than Nektar Therapeutics.
Nkarta has higher earnings, but lower revenue than Nektar Therapeutics. Nkarta is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nkarta has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Summary
Nkarta beats Nektar Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Nkarta News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
